Venetoclax Combined with Hypomethylating Agents for Treatment-Naïve B/Myeloid Mixed Phenotype Acute Leukemia

Overview

Journal Case Rep Hematol

Publisher Wiley

Specialty Hematology

Date 2021 Jan 28

PMID 33505737

Citations 6

Authors

Di Wu

Wenlan Chen

Zhichao Chen

Qiubai Li

Affiliations

Soon will be listed here.

Abstract

Mixed phenotype acute leukemia (MPAL) is a rare hematological malignancy that lacks consensus on optimal management. We report for the first time two cases of treatment-naïve B/myeloid MPAL patients treated with a novel chemo-free regimen using venetoclax combined with hypomethylating agents, which successfully induced complete remission with tolerable toxicities.

Citing Articles

[Blinatumomab-based combination treatment for CD19-positive acute leukemia of an ambiguous lineage].

Wu X, Yang Z, Lu C, Zhang X, Sun A, Zhou H Zhonghua Xue Ye Xue Za Zhi. 2025; 45(11):1051-1054.

PMID: 39746700 PMC: 11886684. DOI: 10.3760/cma.j.cn121090-20240411-00133.

A hybrid protocol CLAG-M, a possible player for the first-line therapy of patients with mixed phenotype acute leukemia. A Polish Adult Leukemia Group experience.

Karasek M, Armatys A, Skarupski M, Bolkun L, Budziszewska K, Drozd-Sokolowska J Front Oncol. 2024; 14:1395992.

PMID: 38835383 PMC: 11148324. DOI: 10.3389/fonc.2024.1395992.

Venetoclax Combination Treatment of Acute Myeloid Leukemia in Adolescents and Young Adult Patients.

Chatzikalil E, Roka K, Diamantopoulos P, Rigatou E, Avgerinou G, Kattamis A J Clin Med. 2024; 13(7).

PMID: 38610812 PMC: 11012941. DOI: 10.3390/jcm13072046.

Multilineage Lymphoblastic Lymphoma as an Initial Presentation of Mixed Phenotype Acute Leukemia.

Ikeda M, Nakahara W, Asako M, Umeki Y, Matsuoka Y, Terakawa T Case Rep Hematol. 2023; 2023:3628712.

PMID: 36879893 PMC: 9985503. DOI: 10.1155/2023/3628712.

Mixed-Phenotype Acute Leukemia: Clinical Diagnosis and Therapeutic Strategies.

George B, Yohannan B, Gonzalez A, Rios A Biomedicines. 2022; 10(8).

PMID: 36009521 PMC: 9405901. DOI: 10.3390/biomedicines10081974.

References

Lee J, Lee S, Lee J, Kim K, Choi M, Lee W . Mixed-phenotype acute leukemia treated with decitabine. Korean J Intern Med. 2016; 31(2):406-8. PMC: 4773716. DOI: 10.3904/kjim.2014.353. View

Wu X, Zhang J, Chen Q, Zhou L, Li M, Qiu H . Efficacy of venetoclax in combination with azacitidine followed by haploidentical transplantation in refractory acute myeloid leukaemia and mixed phenotype acute leukaemia. Br J Haematol. 2020; 189(5):e200-e204. DOI: 10.1111/bjh.16622. View

Takahashi K, Wang F, Morita K, Yan Y, Hu P, Zhao P . Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes. Nat Commun. 2018; 9(1):2670. PMC: 6039465. DOI: 10.1038/s41467-018-04924-z. View

Xu X, Wang J, Lu S, Chen L, Yang J, Zhang W . Clinical and biological characteristics of adult biphenotypic acute leukemia in comparison with that of acute myeloid leukemia and acute lymphoblastic leukemia: a case series of a Chinese population. Haematologica. 2009; 94(7):919-27. PMC: 2704302. DOI: 10.3324/haematol.2008.003202. View

DiNardo C, Pratz K, Pullarkat V, Jonas B, Arellano M, Becker P . Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2018; 133(1):7-17. PMC: 6318429. DOI: 10.1182/blood-2018-08-868752. View

Wolach O, Stone R . Optimal therapeutic strategies for mixed phenotype acute leukemia. Curr Opin Hematol. 2020; 27(2):95-102. DOI: 10.1097/MOH.0000000000000570. View

Valentin R, Grabow S, Davids M . The rise of apoptosis: targeting apoptosis in hematologic malignancies. Blood. 2018; 132(12):1248-1264. DOI: 10.1182/blood-2018-02-791350. View

Shi R, Munker R . Survival of patients with mixed phenotype acute leukemias: A large population-based study. Leuk Res. 2015; 39(6):606-16. DOI: 10.1016/j.leukres.2015.03.012. View

Tallman M, Wang E, Altman J, Appelbaum F, Bhatt V, Bixby D . Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019; 17(6):721-749. DOI: 10.6004/jnccn.2019.0028. View

10.

Benton C, Thomas D, Yang H, Ravandi F, Rytting M, OBrien S . Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia. Br J Haematol. 2014; 167(3):356-65. PMC: 4198465. DOI: 10.1111/bjh.13050. View

11.

Maruffi M, Sposto R, Oberley M, Kysh L, Orgel E . Therapy for children and adults with mixed phenotype acute leukemia: a systematic review and meta-analysis. Leukemia. 2018; 32(7):1515-1528. PMC: 7508489. DOI: 10.1038/s41375-018-0058-4. View

12.

Burke M, Lamba J, Pounds S, Cao X, Ghodke-Puranik Y, Lindgren B . A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia. Am J Hematol. 2014; 89(9):889-95. PMC: 4134715. DOI: 10.1002/ajh.23778. View

13.

Klocke H, Dong Z, OBrien C, Burwick N, Richard R, Wu D . Venetoclax and Decitabine for T/Myeloid Mixed-Phenotype Acute Leukemia Not Otherwise Specified (MPAL NOS). Case Rep Hematol. 2020; 2020:8811673. PMC: 7569429. DOI: 10.1155/2020/8811673. View

14.

Cui J, Xiao Y, You Y, Shi W, Li Q, Luo Y . Decitabine for relapsed acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. J Huazhong Univ Sci Technolog Med Sci. 2017; 37(5):693-698. DOI: 10.1007/s11596-017-1790-0. View

15.

Rahmat L, Nguyen A, Abdulhaq H, Prakash S, Logan A, Mannis G . Venetoclax in Combination with Decitabine for Relapsed T-Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplant. Case Rep Hematol. 2018; 2018:6092646. PMC: 6129347. DOI: 10.1155/2018/6092646. View

16.

Farhadfar N, Li Y, May W, Adams C . Venetoclax and decitabine for treatment of relapsed T-cell acute lymphoblastic leukemia: A case report and review of literature. Hematol Oncol Stem Cell Ther. 2020; 14(3):246-251. DOI: 10.1016/j.hemonc.2019.10.002. View

17.

Getta B, Roshal M, Zheng J, Park J, Stein E, Levine R . Allogeneic Hematopoietic Stem Cell Transplantation with Myeloablative Conditioning Is Associated with Favorable Outcomes in Mixed Phenotype Acute Leukemia. Biol Blood Marrow Transplant. 2017; 23(11):1879-1886. PMC: 5682215. DOI: 10.1016/j.bbmt.2017.06.026. View

18.

Paulson K, Kumar R, Ahsanuddin A, Seftel M . Azacytidine as a novel agent in the treatment of acute lymphoblastic leukemia. Leuk Lymphoma. 2010; 52(1):134-6. DOI: 10.3109/10428194.2010.512965. View